Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Phase II Randomized Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) With or Without Valproic Acid in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia -"SPORE"
Status: Enrolling
Updated:  7/15/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Phase II Randomized Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) With or Without Valproic Acid in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia -"SPORE"
Status: Enrolling
Updated: 7/15/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Personalized Treatment Selection for Metastatic Breast Cancer
Personalized Treatment Selection for Metastatic Breast Cancer
Status: Enrolling
Updated:  7/16/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Personalized Treatment Selection for Metastatic Breast Cancer
Personalized Treatment Selection for Metastatic Breast Cancer
Status: Enrolling
Updated: 7/16/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation
A Prospective, Randomized, Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation.
Status: Enrolling
Updated:  7/16/2015
South Texas Veterans Health Care System
mi
from
San Antonio, TX
Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation
A Prospective, Randomized, Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation.
Status: Enrolling
Updated: 7/16/2015
South Texas Veterans Health Care System
mi
from
San Antonio, TX
Click here to add this to my saved trials
Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer
Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer
Status: Enrolling
Updated:  7/17/2015
Oklahoma University
mi
from
Oklahoma City, OK
Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer
Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer
Status: Enrolling
Updated: 7/17/2015
Oklahoma University
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia
Omega-3 Fatty Acids and Prevention of DCIS and/or ADH: A Translational Approach
Status: Enrolling
Updated:  7/17/2015
Epic Imaging
mi
from
Portland, OR
Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia
Omega-3 Fatty Acids and Prevention of DCIS and/or ADH: A Translational Approach
Status: Enrolling
Updated: 7/17/2015
Epic Imaging
mi
from
Portland, OR
Click here to add this to my saved trials
Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia
Omega-3 Fatty Acids and Prevention of DCIS and/or ADH: A Translational Approach
Status: Enrolling
Updated:  7/17/2015
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia
Omega-3 Fatty Acids and Prevention of DCIS and/or ADH: A Translational Approach
Status: Enrolling
Updated: 7/17/2015
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated:  7/17/2015
DCH Cancer Treatment Center
mi
from
Tuscaloosa, AL
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated: 7/17/2015
DCH Cancer Treatment Center
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated:  7/17/2015
Beverly Oncology
mi
from
Montebello, CA
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated: 7/17/2015
Beverly Oncology
mi
from
Montebello, CA
Click here to add this to my saved trials
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated:  7/17/2015
Florida Radiation Oncology Group
mi
from
Orange Park, FL
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated: 7/17/2015
Florida Radiation Oncology Group
mi
from
Orange Park, FL
Click here to add this to my saved trials
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated:  7/17/2015
St Elizabeth's and Memorial Cancer Center
mi
from
Swansea, IL
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated: 7/17/2015
St Elizabeth's and Memorial Cancer Center
mi
from
Swansea, IL
Click here to add this to my saved trials
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated:  7/17/2015
Cancer Institute of Cape Girardeau, LLC
mi
from
Cape Girardeau, MO
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated: 7/17/2015
Cancer Institute of Cape Girardeau, LLC
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated:  7/17/2015
AtlantiCare Cancer Care Institute
mi
from
Galloway, NJ
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated: 7/17/2015
AtlantiCare Cancer Care Institute
mi
from
Galloway, NJ
Click here to add this to my saved trials
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated:  7/17/2015
Nazha Cancer Center
mi
from
Northfield, NJ
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated: 7/17/2015
Nazha Cancer Center
mi
from
Northfield, NJ
Click here to add this to my saved trials
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated:  7/17/2015
Dallas Surgical Group / Northpoint Cancer Center
mi
from
Dallas, TX
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Electronic Xoft Intersociety Brachytherapy Trial
Status: Enrolling
Updated: 7/17/2015
Dallas Surgical Group / Northpoint Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated:  7/17/2015
Mills Peninsula Hospital
mi
from
San Mateo, CA
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated: 7/17/2015
Mills Peninsula Hospital
mi
from
San Mateo, CA
Click here to add this to my saved trials
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated:  7/17/2015
Wellstar-Kennestone Cancer Center
mi
from
Marietta, GA
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated: 7/17/2015
Wellstar-Kennestone Cancer Center
mi
from
Marietta, GA
Click here to add this to my saved trials
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated:  7/17/2015
Rush University Medical Center
mi
from
Chicago, IL
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated: 7/17/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated:  7/17/2015
Little Company of Mary Hospital
mi
from
Evergreen Park, IL
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated: 7/17/2015
Little Company of Mary Hospital
mi
from
Evergreen Park, IL
Click here to add this to my saved trials
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated:  7/17/2015
Holy Cross Medical Center
mi
from
Silver Spring, MD
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated: 7/17/2015
Holy Cross Medical Center
mi
from
Silver Spring, MD
Click here to add this to my saved trials
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated:  7/17/2015
Beth Israel Med Ctr
mi
from
New York, NY
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated: 7/17/2015
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated:  7/17/2015
Dickstein Cancer Center- White Plains Hospital
mi
from
White Plains, NY
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated: 7/17/2015
Dickstein Cancer Center- White Plains Hospital
mi
from
White Plains, NY
Click here to add this to my saved trials
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated:  7/17/2015
Oklahoma University Health Science Center
mi
from
Oklahoma City, OK
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated: 7/17/2015
Oklahoma University Health Science Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated:  7/17/2015
Rhode Island Hospital
mi
from
Providence, RI
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated: 7/17/2015
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated:  7/17/2015
Swedish Cancer Institute
mi
from
Seattle, WA
Post Market Study Using the Xoft Axxent System
Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer
Status: Enrolling
Updated: 7/17/2015
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast
Status: Enrolling
Updated:  7/18/2015
Northwestern University
mi
from
Chicago, IL
4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast
Status: Enrolling
Updated: 7/18/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  7/18/2015
Arizona Oncology Associates, PC-HAL
mi
from
Pheonix, AZ
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 7/18/2015
Arizona Oncology Associates, PC-HAL
mi
from
Pheonix, AZ
Click here to add this to my saved trials
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  7/18/2015
The Oncology Institute of Hope and Innovation
mi
from
Downey, CA
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 7/18/2015
The Oncology Institute of Hope and Innovation
mi
from
Downey, CA
Click here to add this to my saved trials
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  7/18/2015
Compassionate Cancer Medical Center
mi
from
Riverside, CA
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 7/18/2015
Compassionate Cancer Medical Center
mi
from
Riverside, CA
Click here to add this to my saved trials
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  7/18/2015
Northern Indiana Research
mi
from
Mishawaka, IN
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 7/18/2015
Northern Indiana Research
mi
from
Mishawaka, IN
Click here to add this to my saved trials
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  7/18/2015
Northern Indiana Research
mi
from
South Bend, IN
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 7/18/2015
Northern Indiana Research
mi
from
South Bend, IN
Click here to add this to my saved trials
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  7/18/2015
North Shore Oncology
mi
from
East Setauket, NY
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 7/18/2015
North Shore Oncology
mi
from
East Setauket, NY
Click here to add this to my saved trials
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated:  7/18/2015
Gabrail Cancer Center Research LLC
mi
from
Canton, OH
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Status: Enrolling
Updated: 7/18/2015
Gabrail Cancer Center Research LLC
mi
from
Canton, OH
Click here to add this to my saved trials
Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer
Pemetrexed and LBH589 in Previously-Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/20/2015
Hillman Cancer Center
mi
from
Pittsburgh, PA
Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer
Pemetrexed and LBH589 in Previously-Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/20/2015
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of California Davis Cancer Center
mi
from
Sacramento, CA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of Chicago
mi
from
Chicago, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Montefiore Medical Center
mi
from
Bronx, NY
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
New York University Langone Medical Center
mi
from
New York, NY
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
City of Hope Medical Center
mi
from
Duarte, CA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of Southern California/Norris Cancer Center
mi
from
Los Angeles, CA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of Southern California/Norris Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Decatur Memorial Hospital
mi
from
Decatur, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Loyola University Medical Center
mi
from
Maywood, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Southern Illinois University
mi
from
Springfield, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Southern Illinois University
mi
from
Springfield, IL
Click here to add this to my saved trials